Alzheimer’s disease is a progressive brain disease that destroys memory and thinking skills over time. It is the most common cause of dementia, accounting for the majority of cases, and an estimated 7.2 million Americans age 65 and older currently live with it. Unlike normal age-related forgetfulness, Alzheimer’s causes brain cells to deteriorate and die, leading to a steady decline that eventually interferes with even the most basic daily tasks.
Alzheimer’s Is a Type of Dementia, Not a Synonym
One of the most common points of confusion is the relationship between Alzheimer’s and dementia. Dementia is not a specific disease. It’s an umbrella term describing a wide range of symptoms, including memory loss, impaired reasoning, and difficulty with language or coordination. Alzheimer’s is one specific brain disease that falls under that umbrella, and it’s the most common type. Other forms of dementia include vascular dementia (caused by reduced blood flow to the brain), Lewy body dementia, and frontotemporal dementia. Each has different underlying causes and patterns, though symptoms can overlap.
What Happens Inside the Brain
Two abnormal proteins drive the damage in Alzheimer’s: amyloid-beta and tau. Amyloid-beta clumps together into sticky plaques between brain cells, while tau forms tangled fibers inside the cells themselves. Before these structures cause visible damage, though, smaller soluble forms of both proteins quietly disrupt communication between neurons. This early interference at the connections between brain cells, called synapses, is likely what causes the first memory problems, well before large-scale brain tissue loss becomes apparent.
Both amyloid-beta and tau interfere with a molecular process that is essential for forming new memories. They block the activation of a key protein that neurons rely on to strengthen connections during learning. They also reduce levels of a protective growth factor called BDNF, which neurons need to survive and adapt. Over time, this disruption weakens and kills brain cells, causing the brain to physically shrink. The damage typically starts in areas responsible for memory and gradually spreads to regions controlling language, reasoning, and eventually basic body functions like swallowing and walking.
Early Warning Signs
Memory loss that disrupts daily life is the hallmark early symptom, and it’s the feature that most clearly separates Alzheimer’s from ordinary forgetfulness. Forgetting where you left your keys once in a while is normal. Regularly forgetting recently learned information, important dates, or conversations you just had is not.
The CDC lists 10 warning signs to watch for:
- Memory loss that disrupts daily life
- Challenges in planning or solving problems
- Difficulty completing familiar tasks at home, work, or during hobbies
- Confusion with time or place
- Trouble understanding visual images and spatial relationships
- New problems with words in speaking or writing
- Misplacing things and being unable to retrace steps
- Decreased or poor judgment
- Withdrawal from work or social activities
- Changes in mood or personality
Any one of these on its own doesn’t mean Alzheimer’s. But a pattern of several, especially when they worsen over months, is worth bringing to a doctor’s attention.
How the Disease Progresses
Alzheimer’s is typically described in three stages: mild, moderate, and severe. The pace varies widely from person to person, with the full course lasting anywhere from a few years to two decades after diagnosis.
In the mild stage, which is when most people are diagnosed, the changes become obvious to family and close friends. A person may get lost in familiar places, lose track of belongings (including valuables), struggle with managing finances, or repeat questions. They can still live independently for the most part, but daily functioning starts to slip.
In the moderate stage, confusion deepens significantly. People lose track of where they are, what day or season it is, and may not recognize family members they don’t see regularly. They need help with dressing, bathing, and other self-care. Personality changes often become more pronounced, including agitation, suspicion, or wandering. This is typically the longest stage.
In the severe stage, mental function declines dramatically, and the disease increasingly affects physical abilities. People lose the ability to carry on a conversation, control movement, and eventually swallow. Full-time care becomes necessary.
Risk Factors and Genetics
Age is the biggest risk factor. The vast majority of cases occur after age 65, and risk roughly doubles every five years after that. But Alzheimer’s is not an inevitable part of aging.
Genetics play a significant role. The most important genetic risk factor is a gene variant called APOE-e4. Carrying one copy of this variant increases your risk; carrying two copies increases it substantially. The APOE-e4 gene appears to make the memory centers of the brain particularly vulnerable. A rare form of the disease, early-onset Alzheimer’s, can strike in a person’s 40s or 50s and is caused by inherited mutations in specific genes. Interestingly, people with early-onset Alzheimer’s who don’t carry APOE-e4 often present with unusual symptoms like difficulty with language or visual processing rather than memory loss.
A growing body of evidence points to at least 14 modifiable risk factors that collectively account for a meaningful share of dementia cases worldwide. The 2024 Lancet Commission report identifies these as: lower education, hearing loss, high blood pressure, smoking, obesity, depression, physical inactivity, diabetes, excessive alcohol consumption, traumatic brain injury, air pollution, social isolation, untreated vision loss, and high LDL cholesterol. The last two were newly added based on strengthening evidence. Addressing these factors won’t guarantee prevention, but population-level reductions in smoking and better blood pressure treatment have already contributed to lower age-related dementia rates in some countries.
How Alzheimer’s Is Diagnosed
There is no single test for Alzheimer’s. Diagnosis has traditionally involved cognitive testing, medical history, brain imaging to rule out other causes (like stroke or tumors), and, when needed, a PET scan or a spinal fluid sample to detect amyloid and tau proteins directly.
Blood tests are now changing that picture. A test called PrecivityAD2 measures levels of amyloid-beta and a specific form of tau protein (p-tau217) in a standard blood draw. In clinical studies, this test predicted an Alzheimer’s diagnosis with 88% to 92% accuracy. Measuring p-tau217 alone performed nearly as well as the full panel. The test is commercially available in the United States but is not yet FDA-approved or covered by most insurance plans. Work is underway to establish guidelines for how these blood tests can be rolled into routine clinical care, starting with specialists and eventually primary care.
Current Treatments
Alzheimer’s has no cure, but newer treatments can slow the disease’s progression for the first time. In 2024, the FDA approved donanemab (brand name Kisunla), a medication given as an intravenous infusion every four weeks. It works by targeting and clearing amyloid plaques from the brain. In a clinical trial of over 1,700 people with mild cognitive impairment or mild-stage Alzheimer’s, those receiving donanemab showed a statistically significant reduction in cognitive and functional decline compared to placebo over 76 weeks.
These newer therapies are only for people in the early stages of the disease. They carry a notable side effect: temporary brain swelling, sometimes accompanied by small spots of bleeding, known as amyloid-related imaging abnormalities (ARIA). ARIA usually has no symptoms and resolves on its own, but serious cases can occur, and people who carry two copies of the APOE-e4 gene face a higher risk. Genetic testing is required before starting treatment. Other side effects include headaches and infusion reactions like nausea or changes in blood pressure.
Older medications can help manage symptoms like memory loss and confusion, though they do not slow the underlying disease. The treatment landscape is shifting rapidly, with the focus now on identifying people early enough to benefit from these newer options.
The Toll on Families and Caregivers
Alzheimer’s affects far more people than just those diagnosed. Unpaid caregivers, most of them family members, provide the equivalent of nearly $470 billion a year in free care in the United States. The physical and emotional cost is steep. Nearly 1 in 5 caregivers have at least two chronic health conditions of their own, in part because they routinely neglect their own medical needs.
The financial strain is equally real. Caregivers of someone with dementia spend an average of $9,000 per year out of pocket. About 4 in 10 employed caregivers reduce their work hours, and nearly 2 in 10 stop working entirely. Almost 80% report paying out of pocket for routine expenses on behalf of the person they care for. These numbers help explain why Alzheimer’s ranks among the most expensive conditions in the country, even though much of the cost never shows up in a hospital bill.
The Bigger Picture
Alzheimer’s is the seventh-leading cause of death in the United States, and 2023 data suggest it will likely return to sixth. Between 2000 and 2022, reported deaths from the disease increased by more than 142%, even as deaths from heart disease, stroke, and HIV declined. The number of Americans living with Alzheimer’s is projected to nearly double to 13.8 million by 2060 if no major breakthroughs in prevention or treatment emerge. That trajectory makes early detection, risk factor reduction, and caregiver support not just medical priorities but urgent public health ones.